Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer-Reference-Cited by-同舟云学术

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer

Published:2021-04 Issue: Volume:225 Page:108679
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Chick R. Connor,Clifton G. Travis,Hale Diane F.,Vreeland Timothy J.,Hickerson Annelies T.,Kemp Bohan Phillip M.,McCarthy Patrick M.,Litton Jennifer K.,Alatrash Gheath,Murthy Rashmi K.,Qiao Na,Philips Anne,Lukas Jason,Holmes Jarrod P.,Mittendorf Elizabeth A.,Peoples George E.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference33 articles.

1. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art;Solinas;Breast,2017

2. Immunotherapy in triple-negative breast cancer;Katz;Med. Oncol.,2017

3. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial;Nanda;JAMA Oncol.,2020

4. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and With IHC 1+ or 2;Fehrenbacher;J. Clin. Oncol.,2020

5. Real-world performance of HER2 testing--national surgical adjuvant breast and bowel project experience;Paik;JNCI J. Nation. Cancer Inst.,2002

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving immunotherapeutic solutions for triple-negative breast carcinoma;Cancer Treatment Reviews;2024-11

2. Landscape of HER2-low breast cancer: Insights from a six-year study on prevalence and clinicopathological characteristics;Annals of Diagnostic Pathology;2024-10

3. HER2-Low Breast Cancer: Now and in the Future;Cancer Research and Treatment;2024-07-15

4. Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC);Cancers;2024-05-25

5. Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer;Breast Cancer Research and Treatment;2024-04-24